Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for its duopoly status, says TD Cowen.

TD Cowen has downgraded Novo Nordisk due to concerns over the potential loss of its semaglutide patent and the company's pipeline outlook, despite still seeing a 6% upside for shares.

10 Mar, 09:48 — 10 Mar, 11:25

Post Share

The Story

What 2 sources agree on, dispute, and miss

What sources agree on

TD Cowen downgraded Novo Nordisk
The downgrade is linked to concerns over semaglutide patent loss
The downgrade also cited threats to Novo Nordisk's duopoly status in diabetes and weight loss

Key claims1 agreed · 1 unverified

✓

Novo Nordisk received a broker downgrade on Tuesday

agreed·marketwatch

TD Cowen still sees Novo Nordisk shares adding 6% from current levels

unverified·cnbc

Coverage gaps

TD Cowen's projection of a 6% upside for Novo Nordisk shares

Reportedcnbc

Missingmarketwatch

The Story

Analyzing sources…

Why this matters

Novo Nordisk is a major pharmaceutical company, known for its popular diabetes and weight-loss drugs like Ozempic. A downgrade from a prominent financial firm can impact investor confidence and the company's market valuation, signaling potential shifts in its competitive landscape and future profitability.

Source Diversity

Moderate (27/100)

2 sources— more sources would strengthen this score15/33

Spectrum spread— 2/5 buckets covered8/33

Far L

Left1

Left (1)

cnbc

Center1

Center (1)

marketwatch

Right

Far R

Geographic diversity— 1 region4/34

US2

ℹAll sources from US region

ℹOnly 2 sources cover this story

Political spectrum

LeftCenterRight

cnbc

marketwatch

Outlet rating This story

SourceOutletiGeneral editorial lean of the outletStoryiHow they covered this specific storyToneFactuality

cnbccentercenteranalyticalMostly Factualfactual reporting on financial analyst actions

marketwatchcentercenterneutralMostly Factualstraightforward reporting of financial analyst downgrade

Coverage leans: balanced

The coverage is largely neutral, focusing on financial reporting without significant political framing, with both outlets presenting factual information about the stock downgrade.

Sources

Showing 2 of 2 sources

cnbcMostly Factual1h ago

TD Cowen downgrades Novo Nordisk on concerns over semaglutide patent loss, pipeline outlook

TD Cowen still sees shares of Novo Nordisk adding 6% from here.

Read full article →

marketwatchMostly Factual3h ago